The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.
 
Orazio Caffo
Consulting or Advisory Role - Astellas Oncology; Bayer; Janssen; Sanofi
 
Emilio Bria
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Helsinn Healthcare; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
 
Ugo De Giorgi
Consulting or Advisory Role - Astellas Oncology; Janssen; Sanofi
 
Marcello Tucci
Consulting or Advisory Role - Astellas Oncology; Bayer; Janssen; Sanofi
 
Elisa Biasco
No Relationships to Disclose
 
Lucia Fratino
No Relationships to Disclose
 
Sabrina Rossetti
No Relationships to Disclose
 
Roberto Iacovelli
No Relationships to Disclose
 
Franco Morelli
No Relationships to Disclose
 
Alessandro D'Angelo
No Relationships to Disclose
 
Enrico Campadelli
No Relationships to Disclose
 
Francesco Verderame
No Relationships to Disclose
 
Nicolo Borsellino
No Relationships to Disclose
 
Donata Sartori
No Relationships to Disclose
 
Annalisa Guida
Speakers' Bureau - Astellas Pharma
 
Riccardo Ricotta
No Relationships to Disclose
 
Sandro Barni
No Relationships to Disclose
 
Francesca Maines
No Relationships to Disclose
 
Isabella Sperduti
No Relationships to Disclose
 
Vittorina Zagonel
No Relationships to Disclose